INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.36
+0.69 (+2.41%)
As of 11:37AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close28.67
Open28.36
Bid29.25 x 1200
Ask29.30 x 800
Day's Range28.27 - 29.46
52 Week Range11.31 - 31.58
Volume83,282
Avg. Volume1,032,691
Market Cap2.277B
Beta (3Y Monthly)3.71
PE Ratio (TTM)N/A
EPS (TTM)-4.22
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.10
Trade prices are not sourced from all markets
  • Markit16 days ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    Insmed Inc NASDAQ/NGS:INSMView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for INSM with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding INSM totaled $75 million. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire17 days ago

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., March 4, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to nine new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on March 1, 2019 to purchase an aggregate 10,690 shares of Insmed common stock at an exercise price of $30.96 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of INSM earnings conference call or presentation 22-Feb-19 1:30pm GMT

    Q4 2018 Insmed Inc Earnings Call

  • Insmed Inc (INSM) Q4 2018 Earnings Conference Call Transcript
    Motley Fool27 days ago

    Insmed Inc (INSM) Q4 2018 Earnings Conference Call Transcript

    INSM earnings call for the period ending December 31, 2018.

  • Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
    Zacks27 days ago

    Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

    Insmed (INSM) delivered earnings and revenue surprises of -5.41% and 96.19%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press27 days ago

    Insmed: 4Q Earnings Snapshot

    On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of $1.19. Losses, adjusted for amortization costs, were $1.17 per share. The results fell short of Wall Street expectations. ...

  • Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
    PR Newswire27 days ago

    Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    --ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018-- --Company Provides Full-Year 2019 ARIKAYCE Revenue Guidance of $80 ...

  • Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference
    PR Newswire29 days ago

    Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference

    BRIDGEWATER, N.J., Feb. 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Leerink Partners 8th Annual Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 3:30 p.m. ET. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019
    PR Newswirelast month

    Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019

    BRIDGEWATER, N.J. , Feb. 15, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that ...

  • Is Insmed Incorporated’s (NASDAQ:INSM) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.last month

    Is Insmed Incorporated’s (NASDAQ:INSM) Balance Sheet Strong Enough To Weather A Storm?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-cap and large-cap companies receive a lotRead More...

  • GlobeNewswirelast month

    Market Trends Toward New Normal in lululemon athletica inc, Insmed, Advanced Disposal Services, AGCO, Douglas Dynamics, and Ballard Power — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Options Traders Expect Huge Moves in Insmed (INSM) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Insmed (INSM) Stock

    Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.

  • Benzinga2 months ago

    Top 5 Small-Cap Winners And Losers, Week Of Jan. 7

    In today’s round-up of the previous week’s top five shakers and fakers (i.e. winners and losers,), we see some major jumps or drops depending on how well company announcements were received. For some, ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool2 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?

  • The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
    Motley Fool2 months ago

    The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference

    These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.

  • Here's Why Insmed Rocketed 43% Higher on Monday
    Motley Fool2 months ago

    Here's Why Insmed Rocketed 43% Higher on Monday

    Investors are impressed with early sales numbers for the biotech's Arikayce antibiotic.

  • ETF Trends2 months ago

    Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology

    Biotechnology stocks and sector-related ETFs were among the best performers Monday after Eli Lilly (NYSE: LLY) said it will acquire Loxo Oncology Inc. (NasdaqGS: LOXO) for $8 billion. Among the best performers ...

  • MarketWatch2 months ago

    Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter

    Shares of Insmed Incorporated shot up 18% in after-hours trading Friday after the company announced it expected sales of its antibacterial Arikayce to be $9.8 million for the fourth quarter, with $9.2 million in U.S. sales and $600,000 in sales outside the U.S. The drug is used to treat patients with a lung disease caused by a group of bacteria called Mycobacterium avium complex (MAC) and who do not respond to traditional treatment. Arikayce was granted accelerated approval by the FDA in September. Insmed said more than 500 U.S. patients had started treatment with the drug and approximately 600 physicians had written at least one prescription for the therapy as of Dec. 31. Shares of Insmed have fallen 51% in the past 12 months, while the iShares NASDAQ Biotech ETF has fallen 6.75%. The S&P 500 has fallen 7%.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019
    PR Newswire2 months ago

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019

    BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary unaudited net product sales for the fourth quarter of 2018, and shared the Company's strategic priorities for 2019. ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.